IP Verse

Actavis Group Ptc Ehf competitive analysis

Latest oppositions filed by Actavis Group Ptc Ehf

Explore patent oppositions filed by Actavis Group Ptc Ehf against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
EP2036557
Antitumor Agent For Thyroid CancerEISAI R&D MANAGEMENTJul 18, 2016
EP2318365
Novel Polymorphic Forms Of Perindopril (L)-Arginine And Process For The Preparation ThereofMATRIX LABORATORIESMay 11, 2016
EP2322174
Combined Use Of Valsartan And Calcium Channel Blockers For Therapeutic PurposesNOVARTISMar 3, 2016
EP2801355
Controlled Release Pharmaceutical Compositions Comprising A Fumaric Acid EsterFORWARD PHARMAFeb 19, 2016
EP2266573
Fulvestrant FormulationASTRAZENECAFeb 16, 2016
EP2647399
InhalerBOEHRINGER INGELHEIMJan 29, 2016
EP1773293
Compositions And Methods For Treating Central Precocious PubertyENDO PHARMACEUTICALS SOLUTIONSJan 15, 2016
EP2318419
Boronate Ester Compounds And Pharmaceutical Compositions ThereofMILLENNIUM PHARMACEUTICALSJan 8, 2016
EP1845961
Prevention And Treatment Of Thromboembolic DisordersBAYERJan 6, 2016
EP1492505
Pharmaceutical Preparation Containing Oxycodone And NaloxoneEURO CELTIQUEDec 11, 2015

Latest PTAB cases involving Actavis Group Ptc Ehf

Discover the latest PTAB cases involving Actavis Group Ptc Ehf, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Actavis Group Ptc Ehf with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ACTAVIS GROUP PTC EHF23 - - -
ATNAHS PHARMA UK - 14 - -
EURO CELTIQUE - 73 - -
PROGENICS PHARMACEUTICALS - 713